These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1510424)

  • 61. Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.
    Graham DR; Chertova E; Hilburn JM; Arthur LO; Hildreth JE
    J Virol; 2003 Aug; 77(15):8237-48. PubMed ID: 12857892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cyclophilin A incorporation is not required for human immunodeficiency virus type 1 particle maturation and does not destabilize the mature capsid.
    Wiegers K; Rutter G; Schubert U; Grättinger M; Kräusslich HG
    Virology; 1999 Apr; 257(1):261-74. PubMed ID: 10208939
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.
    Fontana J; Keller PW; Urano E; Ablan SD; Steven AC; Freed EO
    J Virol; 2016 Jan; 90(2):972-8. PubMed ID: 26537676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Obstruction of HIV-1 particle release by interferon-alpha occurs before viral protease processing and is independent of envelope glycoprotein.
    Babé LM; Unal A; Craik CS
    J Interferon Cytokine Res; 1997 May; 17(5):287-93. PubMed ID: 9181467
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of a protease inhibitor in vitro.
    Kuroda MJ; el-Farrash MA; Choudhury S; Harada S
    Virology; 1995 Jun; 210(1):212-6. PubMed ID: 7793073
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Constitutive production of nonenveloped human immunodeficiency virus type 1 particles by a mammalian cell line and effects of a protease inhibitor on particle maturation.
    Babé LM; Craik CS
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2430-9. PubMed ID: 7840583
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein.
    Shehu-Xhilaga M; Hill M; Marshall JA; Kappes J; Crowe SM; Mak J
    J Virol; 2002 May; 76(9):4331-40. PubMed ID: 11932399
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Overexpression and incorporation of GagPol precursor does not impede packaging of HIV-1 tRNA(Lys3) but promotes intracellular budding of virus-like particles.
    Shehu-Xhilaga M; Lee JY; Campbell S; Marshall JA; Crowe SM; Mak J
    J Biomed Sci; 2002; 9(6 Pt 2):697-705. PubMed ID: 12432236
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid Cu1+.
    Davis DA; Branca AA; Pallenberg AJ; Marschner TM; Patt LM; Chatlynne LG; Humphrey RW; Yarchoan R; Levine RL
    Arch Biochem Biophys; 1995 Sep; 322(1):127-34. PubMed ID: 7574666
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Requirement of the Pr55gag precursor for incorporation of the Vpr product into human immunodeficiency virus type 1 viral particles.
    Lavallée C; Yao XJ; Ladha A; Göttlinger H; Haseltine WA; Cohen EA
    J Virol; 1994 Mar; 68(3):1926-34. PubMed ID: 8107252
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Properties of avian retrovirus particles defective in viral protease.
    Stewart L; Schatz G; Vogt VM
    J Virol; 1990 Oct; 64(10):5076-92. PubMed ID: 1697912
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells.
    Liao Z; Graham DR; Hildreth JE
    AIDS Res Hum Retroviruses; 2003 Aug; 19(8):675-87. PubMed ID: 13678470
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles.
    Karacostas V; Wolffe EJ; Nagashima K; Gonda MA; Moss B
    Virology; 1993 Apr; 193(2):661-71. PubMed ID: 7681610
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
    Sei S; Yang QE; O'Neill D; Yoshimura K; Nagashima K; Mitsuya H
    J Virol; 2000 May; 74(10):4621-33. PubMed ID: 10775598
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope.
    Zhou J; Aiken C
    J Virol; 2001 Jul; 75(13):5851-9. PubMed ID: 11390586
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.
    Kaplan AH; Manchester M; Swanstrom R
    J Virol; 1994 Oct; 68(10):6782-6. PubMed ID: 8084015
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stimulated Emission Depletion Nanoscopy Reveals Time-Course of Human Immunodeficiency Virus Proteolytic Maturation.
    Hanne J; Göttfert F; Schimer J; Anders-Össwein M; Konvalinka J; Engelhardt J; Müller B; Hell SW; Kräusslich HG
    ACS Nano; 2016 Sep; 10(9):8215-22. PubMed ID: 27517329
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 80. An active-site mutation in the human immunodeficiency virus type 1 proteinase (PR) causes reduced PR activity and loss of PR-mediated cytotoxicity without apparent effect on virus maturation and infectivity.
    Konvalinka J; Litterst MA; Welker R; Kottler H; Rippmann F; Heuser AM; Kräusslich HG
    J Virol; 1995 Nov; 69(11):7180-6. PubMed ID: 7474139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.